Atara biotherapeutics announces 1-for-25 reverse stock split

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the "reverse stock split"). the reverse stock split will become effective at 12:01 a.m. eastern t.
ATRA Ratings Summary
ATRA Quant Ranking